Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase.

ABSTRACT:

Background

Direct-acting antivirals (DAAs) have transformed the treatment of hepatitis C infection (HCV) globally. Exploratory studies to identify potential rare adverse drug events associated with DAAs to optimize their use are scarce.

Objective

We aimed to describe the most common serious DAA-associated adverse drug reaction (ADR) reports overall and by DAA regimen.

Methods

We conducted a cross-sectional analysis of post-market ADRs associated with DAA therapy using VigiBase, the global database of the WHO Programme for International Drug Monitoring. Reports occurring between 2013 and 2020 in which an eligible DAA brand or regimen was reported as the suspect drug were included and described. Reports of concomitant ribavirin or interferon use were excluded. The top 2

SUBMITTER: Hayes KN 

PROVIDER: S-EPMC8734625 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature